1SCE20260055 - Tyrosine Kinase Inhibitors (Exclusive) 2026
About This Opportunity
TranslatedThis tender, identified as 1SCE20260055, concerns the procurement of exclusive Tyrosine Kinase Inhibitors (TKIs) for the year 2026. Tyrosine kinase inhibitors are a class of targeted therapy drugs used primarily in cancer treatment. They work by blocking the action of specific tyrosine kinases, enzymes that play a crucial role in cell signaling pathways that can lead to uncontrolled cell growth and proliferation. By inhibiting these enzymes, TKIs can slow or stop the growth of cancer cells. The 'exclusive' designation suggests that this procurement might be for specific, potentially patented, formulations or from a sole-source provider, requiring a specialized acquisition process. The tender likely outlines the specific types of TKIs required, quantities, delivery schedules, quality standards, and the evaluation criteria for potential suppliers. This procurement is critical for ensuring the availability of advanced oncological treatments for patients. The tender document will detail the technical specifications, contractual terms, and submission requirements for interested parties wishing to supply these vital medications.
This is a supplies contract in the health and medical services, trade and industry and general supplies sectors, with a focus on Pharmaceuticals and Manufacturing. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 27,600.
Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: PortugueseThis tender, identified as 1SCE20260055, seeks the supply of Tyrosine Kinase Inhibitors (TKIs) exclusively within Portugal. The procurement is being managed through the Portal BASE, the central platform for public contracts in mainland Portugal and its autonomous regions. This indicates a public sector procurement process, likely by a healthcare or governmental entity responsible for medical supplies and pharmaceuticals.
The requirement for TKIs suggests a need for advanced therapeutic agents, commonly used in the treatment of various cancers and other chronic diseases where aberrant cell signaling pathways are involved. Suppliers are expected to provide high-quality, registered pharmaceutical products that meet stringent regulatory standards. Typical requirements for such tenders include proven manufacturing capabilities, adherence to Good Manufacturing Practices (GMP), and the ability to supply products with valid marketing authorizations from relevant European regulatory bodies.
Bidders will likely need to demonstrate their capacity to meet demand, ensure timely delivery across Portugal, and provide comprehensive product documentation, including certificates of analysis and pharmacovigilance information. The "exclusivo" designation implies that only specific types or brands of TKIs may be sought, or that the tender may be restricted to a particular market segment or supplier type, requiring careful review of the detailed tender documents to ascertain the precise scope.
This procurement is a critical step in ensuring the availability of essential, specialized medicines for patients in Portugal.
Data provenance
This notice is sourced from base_gov_pt and was originally published on March 12, 2026. Last refreshed 7 days ago. Original language: Portuguese. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Serviço de Saúde da Região Autónoma da Madeira, EPE-RAM
Serviço de Saúde da Região Autónoma da Madeira, EPE-RAM has issued 324 procurement notices on BidsFactory, including 0 currently open and 307 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Industry & Manufacturing. All notices are published for Portugal. Notices are distributed via base_gov_pt and TED - Tenders Electronic Daily (EU). Most recent publication: June 25, 2026.
Frequently asked questions about this tender
Is this tender still open?
No — the contract has already been awarded to Komtur Pharmaceutical e.K. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Serviço de Saúde da Região Autónoma da Madeira, EPE-RAM in Portugal. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €27,600. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Where will the contract be performed?
The contract is for delivery in Portugal. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit base_gov_pt to access the full notice, required documents, and submission instructions provided by the contracting authority.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.